

FACULTY

ABATE-DAGA LAURA TU.TO.R Associazione Onlus, Milan

BALLATORE ZELMIRA AOU Ospedali Riuniti, Ancona

CONFORTI FABIO IEO Istituto Europeo di Oncologia, Milan

DE BRAUD FILIPPO Full Professor of Medical Oncology, University of Milan, Director Dpt. of Oncology and Hemato-Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

FRANCESCHINI DAVIDE IRCCS Humanitas Research Hospital, Milan

GALLI GIULIA Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

GARASSINO MARINA CHIARA Dpt of Medicine, University of Chicago, USA

GIRARD NICOLAS Institut Curie, Paris, France

LE PÉCHOUX CÉCILE Institut Gustave Roussy, Villejuif Cédex, France

MANTEGAZZA RENATO Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan

MARINO MIRELLA IRCCS Istituto Nazionale Regina Elena, Rome

MENDOGNI PAOLO Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

OTTAVIANO MARGARET Ospedale del Mare and CRCTR Centro Riferimento Tumori Rari della regione Campania, Naples

PEZZUTO FEDERICA Università di Padova, Padua

RUFFINI ENRICO A.O.U. Città della Salute e della Scienza di Torino, Turin

WAKELEE HEATHER Stanford University Medical Center, Stanford, CA, USA

ZUCALI PAOLO ANDREA Dpt of Biomedical Sciences, Humanitas University; Dpt of Oncology, IRCCS Humanitas Research Hospital, Milan

GENERAL INFORMATION

OFFICIAL LANGUAGE

The official language is English

VIRTUAL CONFERENCE

The webinar will be held as a video conference on digital platform.

The organizing secretariat will email the credentials for access.

REGISTRATION

Registration online is free of charge:
www.events-communication.com/event/

CERTIFICATE OF PARTICIPATION AND CREDITS

The accreditation approval has been granted by the Accreditation Council of Oncology in Europe. ACOE has awarded 5 credits to this activity (CME - 2734). 6 C.M.E. credits for Italian participants only for the following disciplines: Medical oncology, Radiation oncology, Thoracic surgery, Pathology, Family medicine, Neurology, Immunology, Rheumatology, Nursing. In order to receive credits, participants must: attend at least 90% of the accredited CME session; complete online the CME test and the evaluation forms. CME certificate will be sent by email at the end of the validation procedure (within 90 days) A participation certificate will be available at the conclusion of the meeting.

ORGANIZING SECRETARIAT /CME PROVIDER



Events srl - Provider ECM n.1023
Via Mantegna 1 – 60019 Senigallia (AN)
Ph. +39. 071.7930220 - Fax +39 071.9252094
segreteria@events-communication.com
www.events-communication.com

PATRONAGES UNDER THE AUSPICES OF



Network Adult Cancers (ERN EURACAN)

TETs SumUP

Summer Update on Thymic Epithelial Tumors

WEBINAR - JULY 7, 2021



Fondazione IRCCS Istituto Nazionale dei Tumori

Sistema Socio Sanitario

Regione Lombardia

BACKGROUND AND RATIONALE

Thymic epithelial tumors (TETs) are rare malignancies, with a cumulative incidence of 1.3-3.2 cases/1,000,000, that is about 230 new cases/year in Italy.

The diagnosis and treatment of TETs require the presence of a multidisciplinary team including at least a Medical Oncologist, a Thoracic Surgeon, and a Radiation Oncologist. The collaboration of a Neurologist and an Immunologist is also useful, due to the possible association with TETs of several paraneoplastic syndromes.

Furthermore, the rarity of TETs hinders the conduction of clinical trials and translational research, so that the generation of high-level scientific evidence is hard.

In the end, the complexity and extreme rarity of TETs often imply unequal standards of care and a lack of shared guidelines. This worsens the problem of difficult access to high-quality care, which is a common concern for TET patients.

All these considerations have led Fondazione IRCCS Istituto Nazionale dei Tumori (INT), which is a national and international reference Institution for TETs, to be promoter and co-founder of TYME (ThyYmic MalignasiEs) network in 2014. TYME aims to promote collaboration among the Centers with specific multidisciplinary expertise on TETs. TYME objectives include: improvement and standardization of therapeutic standards; sharing of treatment principles and guidelines; support to research at both national and international levels.

Since 2017, INT has also been a member of the European reference network for rare thoracic cancers (EURACAN-ERNs). ERNs aim to create collaborations among European excellence Centers for sharing of knowledge and coordination of care about rare diseases.

The purpose of this international conference is to share knowledge on crucial topics related to the diagnosis and treatment of TET patients. It also aims to promote discussion among paramount speakers of controversial clinical cases. This approach will further clarify the need for patients' referral to Centers with high expertise on the disease and a dedicated multidisciplinary team.

SCIENTIFIC COORDINATOR

GIULIA GALLI

Thoracic Unit- Medical Oncology
Fondazione IRCCS Istituto Nazionale
dei Tumori, Milan

SCIENTIFIC COMMITTEE

LAURA ABATE-DAGA

Thoracic Unit-Medical Oncology
Fondazione IRCCS Istituto Nazionale
dei Tumori, Milan

FILIPPO DE BRAUD

Full Professor of Medical Oncology, University of Milan,
Director Dpt. of Oncology and Hemato-Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

GIULIA GALLI

Thoracic Unit-Medical Oncology
Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan

MARINA CHIARA GARASSINO

Professor of Medicine,
Director Thoracic Oncology Program
Dpt. of Medicine, The University of Chicago, USA

SCIENTIFIC PROGRAM

14:00 Welcome and general introduction
Filippo de Braud, Giulia Galli

1st SESSION: Networks and Associations

Chair: Giulia Galli

14:15 Networks and registries
(EURACAN, ITMIG, RYTHMIC)
Nicolas Girard

14:30 Patients' Associations
Laura Abate-Daga

2nd SESSION: Diagnosis

Chair: Paolo Andrea Zucali

14:45 Pathologic diagnosis and staging
Mirella Marino

15:00 Clinical cases: diagnostic challenges and
importance of pathologic revisions
Federica Pezzuto

15:10 Q&A

3rd SESSION: Surgery

Chair: Giulia Galli

15:20 Indications and guidelines
Enrico Ruffini

15:35 Clinical cases: role and importance of surgery
Paolo Mendogni

15:45 Q&A

15:55 Break

4th SESSION: Radiation therapy

Chair: Paolo Andrea Zucali

16:15 Indications and guidelines
Cécile Le Péchoux

16:30 Clinical cases: role and importance of
radiation therapy
Davide Franceschini

16:40 Q&A

5th SESSION: Medical treatment

Chair: Giulia Galli

16:50 Chemotherapy and targeted agents
Marina Chiara Garassino

17:05 Immunotherapy and innovative drugs
Heather Wakelee

17:20 Clinical cases:
strategy of choice of medical therapy
Zelmira Ballatore

17:30 Q&A

6th SESSION: TET-associated diseases

Chair: Paolo Andrea Zucali

17:40 Neurologic diseases
Renato Mantegazza

17:55 Other immune-mediated diseases
Margaret Ottaviano

18:10 Q&A

DISCUSSION WITH THE EXPERTS

Chairs: Giulia Galli, Paolo Andrea Zucali

18:20 Discussion of complex clinical cases:
simulation of a multidisciplinary
tumor board
Fabio Conforti

Experts: **Nicolas Girard**
Cécile Le Péchoux
Enrico Ruffini
Heather Wakelee

18:50 Conclusive remarks
Giulia Galli